Search Results

NGM Biopharmaceuticals, Inc. announced that it has entered into a definitive Agreement and Plan of Merger under which Atlas Neon Parent, Inc. and Atlas Neon Merger Sub, Inc. will acquire NGM Bio through a cash tender offer to be commenced by Merger Sub for all outstanding shares of NGM Bio not held by affiliates of The Column Group, LP and certain other stockholders, as described below, at a price per share of $1.55 in cash.

Waters Corporation introduced new GTxResolve Premier Size Exclusion Chromatography 1000Å 3-micron Columns.

InduPro, Inc. announced an $85 million Series A financing co-led by The Column Group and Vida Ventures with participation from investors, including MRL Ventures Fund, Emerson Collective and Euclidean Capital.

Generating cutting-edge therapeutics requires precision, safety, and efficiency from manufacturing equipment.

ChromaTan, a bioprocessing and biotools advanced biomanufacturing technology platform development company, is excited to announce the award of NIH IIB grant of $2M from the National Institute of General Medical Sciences, for the development and integration of ChromaTan’s novel BioRMB™ single-use, column-free, steady-state continuous counter-current elution technology for manufacturing AAVs.

After completing a buyout transaction with The Column Group to remove it from the stock exchange, NGM Bio has raised a $122M Series A to fund a registrational study for a rare liver disease drug and a Phase II trial in hyperemesis gravidarum.

Remix Therapeutics (Remix) today announced the close of a $60 million financing led by The Column Group.

Kenai Therapeutics today announced an $82 million Series A financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group, with participation from Euclidean Capital and Saisei Ventures.